Abstract
Osteoporosis is the most common bone disease in humans and it can affect people of all ethnic backgrounds, especially older women and men. In osteoporosis, the low bone mass and microarchitectural deterioration of bone tissue lead to enhanced bone fragility and an increased susceptibility to fractures. The process of repair occurs in bone remodeling, which lasts about 6 months. The most common form of osteoporosis, experienced by postmenopausal women, results from reduced estrogen production, which disrupts the fine balance of the bone remodeling cycle as well as bone resorption. Bisphosphonates (BPs) have been the principal anti-resorptive agents used in the therapy of osteoporosis and they work because of two key properties: (1) strong binding to bone due to a high affinity for hydroxyapatite and (2) their ability to inhibit osteoclast function by inhibiting the enzyme farnesyl-diphosphate synthase. The major treatment goal for patients with osteoporosis is to prevent fractures by maintaining or increasing bone mineral density and reducing excessive bone turnover. Bisphosphonates are well tolerated, but, in many cases oral dosing options have failed because some patients suffer severe upper gastrointestinal tolerance problems or esophageal abnormalities. As a consequence, a range of novel BP-dosing options and formulations (intravenous) have been developed to address these varied circumstances.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
US Department of Health and Human Services (2004) Bone Health and Osteoporosis: a report of the surgeon general. US Department of Health and Human Services, Office of the Surgeon General, Rockville
NIH National Institute of Health (2001) NIH Consensus development panel on Osteoporosis prevention, diagnosis and therapy. Osteoporosis prevention, diagnosis and therapy. JAMA 285:785–795
WHO World Health Organization (2003) Prevention and Management of Osteoporosis. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 921:1–164
Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342
Freeman R (2010) Skeletal implications of reproductive aging. Semin Reprod Med 28:422–425
Clarke BL, Khosla S (2010) Physiology of bone loss. Radiol Clin North Am 48:483–495
Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936
Clarke BL, Khosla S (2010) Female reproductive system and bone. Arch Biochem Biophys 503:118–128
Cummings SR, Melton LJ III (2002) Epidemiology and outcomes of osteo-porotic fractures. Lancet 359:1761–1767
Gaines JM, Narrett M, Parrish JM (2010) The effect of the addition of osteoporosis education to a bone health screening program for older adults. Geriatr Nurs 31:348–356
Rao SS, Budhwar N, Ashfaque A (2010) Bisphosphonates are the first-line agents for treating osteoporosis in men. Am Fam Physician 82:503–508
IMS HEALTH (2008) National prescription audit plus TM
Russell R (2006) Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 1068:367–401
Nancollas GH, Tang R, Phipps RJ et al (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627
Kanis JA on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK
Kanis JA, Johnell O, Oden A et al (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397
Chapurlat RD, Delmas PD (2006) Drug insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2:211–219
Goh S, Yang K, Koh J et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy. J Bone Joint Surg Br 89:349–353
Odvina CV, Zerwekh JE, Rao DS et al (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301
Sellmeyer DE (2010) Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 304:1480–1484
Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304–1306
Giusti A, Hamdy NA, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone 47:169–180
Miller PD, McClung MR, Macovei L et al (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-Year results from the MOBILE study. J Bone Miner Res 20:1315–1322
Sambrook PN, Rodriguez JP, Wasnich RD et al (2004) Alendronate in the prevention of osteoporosis: 7-Year follow-up. Osteoporos Int 15:483–488
Ste-Marie LG, Sod E, Johnson T et al (2004) Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 75:469–476
Cramer JA, Amonkar MM, Hebborn A et al (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460
Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861
Penning-van Beest FJ, Goettsch WG, Erkens JA et al (2006) Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis. Clin Ther 28:236–242
Berry SD, Misra D, Hannan MT et al (2010) Low acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation setting. Aging Clin Exp Res. 22:231–237
Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99–102
Black DM, Schwartz AV, Ensrud KE et al (2006) for the FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX). A randomized trial. JAMA 296:2927–2938
Schnitzer T, Bone HG, Crepaldi G et al (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 12:1–12
Lyles KW, Colón-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809
Reginster J-Y, Adami S, Lakatos P et al (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654–661
Acknowledgement
The authors thank Dr. Filippo Zagarella for his skillful technical assistance.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Milan
About this chapter
Cite this chapter
De Sarro, A., Minutoli, L. (2012). Use of Bisphosphonates in Osteoporosis. In: De Ponte, F. (eds) Bisphosphonates and Osteonecrosis of the Jaw: A Multidisciplinary Approach. Springer, Milano. https://doi.org/10.1007/978-88-470-2083-2_5
Download citation
DOI: https://doi.org/10.1007/978-88-470-2083-2_5
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2082-5
Online ISBN: 978-88-470-2083-2
eBook Packages: MedicineMedicine (R0)